Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$75.95−2.25 (-2.88%)
Close on Nov 18, 2026Market cap $3.33BP/E –Yield 0.00%
Tarsus Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tarsus Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$48.54M. For fiscal 2025 it was -$70.97M. The highest annual figure on record is -$4.30M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$70.97M | – |
| FY2024 | Dec 31, 2024 | -$120.57M | – |
| FY2023 | Dec 31, 2023 | -$143.16M | – |
| FY2022 | Dec 31, 2022 | -$62.71M | – |
| FY2021 | Dec 31, 2021 | -$12.16M | – |
| FY2020 | Dec 31, 2020 | -$27.00M | – |
| FY2019 | Dec 31, 2019 | -$4.30M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.91M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.53M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.18M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$24.42M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.16M | – |
| Q2 FY2024 | Jun 30, 2024 | -$33.30M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$44.45M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.94M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$24.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.06M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.22M | -171.7% |
| Q1 FY2022 | Mar 31, 2022 | -$19.52M | -282.2% |
| Q4 FY2021 | Dec 31, 2021 | -$14.45M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.71M | – |
| Q2 FY2021 | Jun 30, 2021 | $7.28M | – |
| Q1 FY2021 | Mar 31, 2021 | $10.71M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.48M | – |
| Q3 FY2020 | Sep 30, 2020 | -$10.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.12M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.08M | – |
| Q3 FY2019 | Sep 30, 2019 | -$633.00K | – |
See a number that looks wrong?